Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our modelAll three major indices are trading down today with the Dow Jones Industrial Average (^DJI) trading down 115 points (-0.8%) at 13,894 as of Monday, Feb. 4, 2013, 11:49 AM ET. The NYSE advances/declines ratio sits at 654 issues advancing vs. 2,230 declining with 132 unchanged.The Health Services industry currently sits down 0.9% versus the S&P 500, which is down 0.9%. On the negative front, top decliners within the industry include Thermo Fisher Scientific (TMO), down 2.6%, Life Technologies (LIFE), down 2.2%, Waters Corporation (WAT), down 2.3%, Stryker Corporation (SYK), down 1.3% and DaVita HealthCare Partners (DVA), down 1.2%.TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today:4. Opko Health (OPK) is one of the companies pushing the Health Services industry higher today. As of noon trading, Opko Health is up $0.28 (4.2%) to $7.01 on average volume Thus far, 1.4 million shares of Opko Health exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $6.70-$7.03 after having opened the day at $6.80 as compared to the previous trading day's close of $6.73. Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies primarily in the United States, Chile, and Mexico. Opko Health has a market cap of $1.9 billion and is part of the health care sector. Shares are up 33.5% year to date as of the close of trading on Friday. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.TheStreet Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report now.It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE
Latest Headlines about CYBX
Latest from TheStreet Wire
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV